{"database": "lobbying", "table": "lobbying_activities", "rows": [[1229429, "2db75f22-fb21-418f-8e2d-515eaa20363a", "Q1", "CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.", 8511, "ONYX PHARMACEUTICALS", 2012, "first_quarter", "MED", "Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages.  HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act;   \nNo Bill #: Prescription Drug User Fee Act reauthorization", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", 30000, null, 0, 0, "2012-04-17T13:10:42.267000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1229429"], "units": {}, "query_ms": 0.8752190042287111, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}